Valeant Pharma (VRX) Income Statement

Click line-items for a historical chart and %

Revenues:
Product sales	219.46M
Service revenue	4.4M
Alliance revenue	31.72M
Total revenues	255.57M
Costs and expenses:
Cost of goods sold (excluding amortization)	60.64M
Cost of services	3.28M
Selling, general and administrative	73.49M
Research and development costs, net	11.95M
Special charges and credits	1.01M
Restructuring and acquisition-related costs	10.71M
Amortization expense	22.34M
Total costs and expenses	183.41M
Income from operations	72.17M
Other income (expense), net including translation and exchange	-1.41M
Gain on early extinguishment of debt	0
Interest income	387K
Interest expense	-20.56M
Income from continuing operations before income taxes	50.59M
Provision for income taxes	18.35M
Income from continuing operations	32.24M
Income (loss) from discontinued operations, net of tax	17K
Net income	32.25M
Less: Net income attributable to noncontrolling interest	1K
Net income attributable to Valeant	32.25M
Basic income per share attributable to Valeant:
Income from continuing operations attributable to Valeant	0.42
Income from discontinued operations attributable to Valeant	0
Net income per share attributable to Valeant	0.42
Diluted income per share attributable to Valeant:
Income from continuing operations attributable to Valeant	0.39
Income from discontinued operations attributable to Valeant	0
Net income per share attributable to Valeant	0.39
Shares used in per share computation - Basic	77.14M
Shares used in per share computation - Diluted	82.64M

Entities mentioned with VRX